Patients HCP
This site is for US Health Care Professionals only
FIRST FDA-APPROVED TARGETED TREATMENT FOR METex14 in mNSCLC
FIRST FDA-APPROVED TARGETED TREATMENT FOR METex14 in mNSCLC

Choose TABRECTA for
your patients with
METex14 in mNSCLC

SEE DATA

Capmatinib (TABRECTA® tablets) is an NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) CATEGORY 2A (PREFERRED) FIRST-LINE TREATMENT option for patients with METex14-positive mNSCLC1*

Efficacy

Efficacy of TABRECTA® (capmatinib) tablets

Discover clinical outcomes in treatment-naive and previously treated patients.

Explore the data ->
METex14 mutation

Testing for MET Exon 14 Skipping

Find out why, when, and how to test for biomarkers in mNSCLC, including METex14, and learn about the FDA-approved companion diagnostics for TABRECTA® (capmatinib) tablets.

Learn about testing ->
Safety

Safety Profile for TABRECTA® (capmatinib) tablets

Learn about common adverse reactions and explore management strategies.

View safety ->
Dosing
Dosing & Administration

Review the dosing details for TABRECTA® (capmatinib) tablets, including how to manage adverse reactions.

See dosing ->
hand icon

Resources

Find informational resources about TABRECTA® (capmatinib) tablets for your practice and patients.

Find resources ->
cost icon

Access & Co-pay

Novartis Oncology can help provide your patients with the right support at the right time.

Explore programs ->
video icon

Video Library

Check out the video library to learn about the mechanism of action and treatment with TABRECTA® (capmatinib) tablets.

Watch now ->

MET, mesenchymal-epithelial transition; METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other options.